Neuren Pharmaceuticals (ASX:NEU) is advancing preparations for a phase 3 trial of its drug candidate NNZ-2591 in children with Phelan-McDermid syndrome, according to a Monday filing with the Australian Securities Exchange.
The Phelan-McDermid syndrome is a rare genetic disorder characterized by the loss or structural change in a portion of chromosome 22.
The announcement follows a meeting with the US Food and Drug Administration in which the company and the US FDA reached alignment on key aspects of the program, with the company submitting additional information to confirm endpoints for the primary efficacy assessment
The 13-week program is a single randomized, double-blind, placebo-controlled trial, the filing said.
Shares rose almost 3% in recent Monday trade.
Price (AUD): $14.43, Change: $+0.38, Percent Change: +2.70%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.